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:
Summary: Quality control is an essential element in clinical laboratory investigations. In the basic programs for
quality control used in recent years accuracy control has been carried out through a comparison with method-
dependent assigned values. With this System the "accuracy" of results from different laboratories is relative, and
comparability is assured only when the laboratories use the same analytical method. Considering the steadily
increasing variety of methods and equipment, a meaningful exchange of Information in patient care, teaching and
research is becoming more and more difficult; but clinical requirements make such an exchange essential.
In this paper a new concept for quality control is presented for discussion. In the basic program incorporating the
new concept the method-dependent assigned values are replaced by reference method values, which are method-
independent. In addition to accuracy control, an ongoing monitoring prccedure using a Shewhart control chart is
also carried out. The maximum allpwable.day-to-day imprecision and the maximum allowable deviation from the
reference method value are fixed on the basis of clinical requirements. This means that the ratio of biological Varia-
tion to analytical between-day imprecision should be ^  2. If the biological Variation is unknown, then the reference
interval is used in its place; the quotient, reference interval/analytical between-day imprecision, should then be ^  8.
The decision limits for the interlaboratory surveys should be fixed in an analogous manner independent of the
analytical method.
After the introduction of quality control based on the new concept the results from different laboratories would be
comparable to the extent dictated by clinical requirements.
The main principles underlying the new concept and the effects of using the new approach are presented for discus-
sion, and the reader is invited to submit comments in writing.
Neues Konzept für die Qualitätssicherung klinisch-chemischer Befunde aufgrund der ärztlichen Erfordernisse
basierend auf Referenzmethoden-Werten
Zusammenfassung: Die Qualitätskontrolle ist ein unerläßlicher Bestandteil der klinisch-chemischen Untersuchungen.
Bei den in den vergangenen Jahren benutzten Basisprogrammen für Qualitätskontrolle erfolgt die Richtigkeitskon-
trolle durch den Vergleich mit methodenabhängigen Sollwerten. Dadurch ist die „Richtigkeit" der Ergebnisse aus
verschiedenen Laboratorien relativiert und die Vergleichbarkeit nur bei denjenigen Laboratorien gewährleistet, die
dieselbe Analysenmethode benutzen. Bei der ständig zunehmenden Vielfalt von Methoden und Geräten ist dies ein
schwerwiegendes Hindernis für den Informationsaustausch bei der Krankenbehandlung, der Forschung und der
Lehre; dies widerspricht den medizinischen Erfordernissen.
In der vorliegenden Arbeit wird ein neues Konzept für die Qualitätskontrolle zur Diskussion gestellt. In dem
Basisprogramm nach dem neuen Konzept treten an die Stelle der methodenabhängigen Sollwerte die methoden-
unabhängigen Referenzmethoden-Werte. Neben dieser Richtigkeitsköntrolle wird eine ständige Kontrolle mit einer
Shewhart -Kontrollkarte durchgeführt. Die maximal zulässige Analysenstreuung von Tag zu Tag und die maximal zu-
lässige Abweichung vom Referenzmethoden-Wert werden aufgrund der medizinischen Erfordernisse festgelegt.
Danach soll der Quotient Biologische Streuung/Analysenstreuung von Tag zu Tag ^  2 sein. Falls die biologische
Streuung nicht bekannt ist, wird an deren Stelle das Referenzintervall benutzt; der Quotient Referenzintervall/
Analysenstreuung von Tag zu Tag soll ^  8 sein.
Die Bewertungsgrenzen für die Ringversuche werden nach analogen Überlegungen unabhängig von der Analysen-
methode festgelegt.
Nach der Einfuhrung der Qualitätskontrolle nach dem neuen Konzept wären die Ergebnisse aus verschiedenen
Laboratorien dann im Rahmen der medizinischen Erfordernisse vergleichbar. Die wesentlichen Grundlagen des
neuen Konzeptes und seine Auswirkungen werden zur Diskussion gestellt und die Leser zu schriftlichen Stellung-
nahmen eingeladen.
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Introduction
The necessity for quality control of clinical laboratory
investigations is taken for granted these days. A great
deal has been accomplished in the past (1-6), but
much is still left to be done. There is general dissatis-
faction with the current Situation (7). The purpose of
this paper is not to present a new approach in a neat
package, but rather to stimulate a discussion, with the
goal of clarifying what is necessary in the future and on
vvhat points a consensus can be reached.
The profusion of problems cannot and should not be
discussed and worked on at the national level. The
discussion should not be limited by the boundaries of
countries, of traditions or of current national legisla-
tion. In the course of the discussion it should also
become evident where there are different approaches
and different needs. ·
As a basis for the discussion I have formulated a
nümber of Statements. They deal with:
1. Basic principles of reliability control within the
framework of clinical laboratory investigations.
2. Parameters for describing reliability.
3. Suggestions about how to measure these parameters.
4. Tolerance limits for the parameters for different
medical questions.
In the following Statements the goal of quality control
and the framework in which quality control occurs,
i.e. the clinical laboratory investigation and the various
steps it encompasses, are also outlined. In formulating
the Statements I have limited myself to quantitative
analytical results that are based on continuous scales.
Other scales sometimes require different procedures.
In order that we can also establish what Views we all
have in common, these Statements include many points
that in my opinion are not controversial and thus not
the subject of dispute.
Statements for Discussion
1. The goal of clinical laboratory investigations has
always been to obtain reliable findings.
2. A prerequisite for reliable findings is reliable analy-
tical results.
3. After an analytical methpd has been developed,
the reliability criteria (l, 2) for this method must
be evaluated and then given in detail along with the
method of evaluation when the method is published
(tab. 1). Reliability criteria are defined, procedures
for evaluating the reliability of methods are described
(l, 12). Reliability criteria have prövided valuable
Information regarding the use of partieular methods
in clinical laboratory investigations.
4. A prerequisite for the evaluation and comparison
of routine methods is the existence ofreference . .
methods (8,11). There are three classes ofreference
methods. The methods in Class A and Class B require
reference materials for calibration (calibration
materials) (tab. 2). · r
5. It is well known that reference methods are un-
suitable for routine investigations. For the latter
routine methods must be developed, Routine
methods may make use of the same analytical
principle äs reference methods.
6. In the past it Jias become cleaf that it is not suffl·
cient to evaluate the reliability of a routine method
only at the tinle the method is flrst developed and
Tab. 1. Reliability criteria (fröm Stamm (11)).
Criterion Definition
Precision Agreement between replicate measurements.
(1,8) It has no numericäl value.
Imprecisioii Standard deviation or coefficient of Variation
(1,8) of the results in a set of replicate measure-
ments. The mean and ntimber pf replicates
must be stated, and the design (within-day,
between-day, between-rlabpratory) described.
Accuracy Agreement between the best estimate of a
(l, 8) quantity and its "true valüe." It has no numericäl
value.
Inaccuracy Numericäl difference between the mean of a set
(1,8) of replicate measurements arid the "trüe value."
This difference (positive or negative) may t>e
expressed in the umts in which the q-üäntity is
measured or äs a percentage of the "true value."
Specificity The abüity of an analytical methpd to deter-
(8, 9) mine solely the component(s) it purports to
measure.
Detection limit Aöalyticäl result which is cleariy detectäble
(8,10) and different from the background noise;
defined äs three Standard deviations of the
appropriate blank value.
Tab. 2. Hierarchy of analytical methods and analytical results.
Method Result
Definitive method
Reference method
Class A: tested with definitive method
Class B: not tested with definitive method,
but highly purified, defined
Standard available, reliability of
method assured
Class C: no homogeneous Standards of known
composition available, testing with
definitive method not possible
Routine method
Class A: systematic error known (selected
method = ausgewählte Methode)
Class B: systematic error not known
. . . . . . — = — . — - .-r——
"true value"
definitive value
reference methpd
value
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published. Rather, it is also necessary to evaluate
some of the reliability criteria when the method is
introduced into a laboratory, and other criteria
must even be subject to an ongoing monitoring
process, i.e. quality control. The objectives of
quality control are summarized in table 3.
7. In the Federal Republic of Germany there is a
basic program for quality control that has proven
effective (tab. 4). Control specimens are used in this
basic program (11,13,14).
Tab. 3. Requirements to be met by an optimal quality control
system (modified from Büttner (1967), Z. Klin. Chem.
KUn. Biochem. 5, 44).
1. Monitoring of random errors = precision control.
2. Monitoring of systematic errors = accuracy control.
3. Monitoring of the effects of the matrix on precision,
accuracy and specificity.
4. Monitoring of trends.
5. Monitoring over the whole clinically relevant ränge of con-
centrations.
6. Ongoing applicability.
7. Deviations immediately recpgnizable.
8. Applicability with mechanized analytical Systems.
9. Time and expense within acceptable limits.
10. Applicability of the basic program from laboratory at
physician's office to central laboratory.
11. Specially träined staff not required.
Tab. 4. Basic program according to the Guidelines of the Medical
Society of West Germany.
1. Internql quality control
a) Precision control
at the most frequent decision limit, by analyzing samples
of the säme control specimen in every run of analyses.
b) Control of accuracy
over the whole clinically relevant ränge of measurement,
by analyzing an accuracy control specimen in every 4th
run pf analyses, the control specimen being selected from
a number of different control specimens kept on band.
2. External quality control
in the form pf shört-tenn interlaboratory sürveys, with at
least two control specimens having different concentrations.
8. Accuracy control äs part of intemal quality cohtrol
and in iiiterlaböratory sürveys is'bäsed on ässigned
values that are metjiodrdependent. The ässigned
values are detennined in high-quality labpratories
that are feferred to äs reference laboratories (15).
As is generally known, the differenees between
ässigned values obtained with different methods can
be so large that this affects the elinical use of the
results (tab. 5).
9. The explanation for these differenees (l 1) can be
found in the fact that the analytical results contain
different components (tab. 6).
Tab. 5. Ässigned values for creatinine - Reg. No. 28300.
Component
Creatinine
(mg/dl) .
Method of analysis
Jaffa reaction after ad Sorption
on fuller's earth, with deproteini-
zation
Ässigned
value
1.23
Enzymatic 1.15
Jaffa reaction, deproteinization 1.5
with trichloroacetic acid
Jaffa reaction, deproteinization 1.8
with picric acid
Jaffa reaction, without deproteini- 1.65
zation, kinetic
Jaffa reaction, AutoAnalyzer®!, l .45
II, SMA
Jaff reaction, without depro- 1.23
teinization, with phosphate buffer,
kinetic
Tab. 6. Components of analyticai results.
Solutions
(Index)
Primary
Standard
solütion (S)
Control
specimen (C)
Patient
specimen (P)
Read- Components
ing
Best
esti-
mate
of
"true
value"
(A) (T)
AS CTS
AC CTC
Ap CTP
Defl-
ciencies
in pro-
cedure
(D)
±CDS
±CDC
±CDP
Non-
speci-
fic
com-
ponent
(N)
±^NC
±CNP
Inter-
fer-
ence
com-
pon-
ent
(D
±cn?
Result,
e.g-
con-
centra-
tion
= ^S
= ^C
= CP
10. Many of the rionspecific components in the analytical
results are now known, but some are still unknown.
The sürh of the major and minor components and
the structures in which the analyte is embedded is
referred to äs the matrix (11). Matrix effects can be
quite large.Matrix effects must be monitored on an
ongoing basis for routine methods. This requires
suitable contröl specimens with a matrix that is äs
similar äs possible to that of the patient specimens.
i 1. The more specific the routine method, the smaller
the matrix effects.
For reference methods there are, by definition,
no matrix effects.
12. If the accuracy ofa method is monitored with
method-dependentflss&flerf values this "accuracy"
is a relative measure. The comparability of results
obtained with different methods is rnarkedly
limited by this fact. This is true also for the ex-
change of Information in patient care and in teaching
and research.
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13.//? the futitre, accuracy control should therefore take
place, whenever possible, by comparing analytical
results with reference method values. This yields a
reliable control of accuracy.
14. Reference method values obtained from accuracy
control specimens with a natural matrix may not
be used to calibrate routine methods. The readings
obtained with routine methods can be greatly
affected by undefmed nonspecific components.
This markedly reduces the reliability of the measure-
ments.
15. Therefcfre pure, carefully defined calibration materiah
vvithout nonspecific components are required/öA*
calibration of routine methods.
Calibration materials and control materials must meet
very different requirements (16).
Tab. 7. Steps in clinical laboratory investigations.
Interference factors include all factors that alter the
result in vitro, i.e. after the sample has been collected
from the patient. They can be divided into two
groups:
1. Interference factors that chang& the concentration
ofthe parameter to be measured in vitro (e.g. potas-
sium elevation caüsed by haeinolysis äs a result of
fälse specimen eollection technique).
2. Interference factors that are different from the
parameter to be measured (e.g. interference by
haempglobin in bilifubin determination,
interference by drugs in the analysis).
They can be eliminated by improving the analytical
pröcedure, especially the specificity.
Efficacy of test result q ftf " / / /^JLVlcUlt/dl
action,
e.gf diagnosis *—
!...>
p.-.·.":.--?
F „ ·
iaJ
-?3|
Medical assessment
Biological
influence factors
Clinical chemical
Plausibility check
Preparations for analysis Interference factors
Reliability check'
Specimen • Analysis
- "^
Analytical result
16. The allowable deviation from the reference method
values depends on the reason for performing a parti-
cular investigation. In order to be able to specify the
tolerance limits the effects ofthe deviation on the
other Steps in the clinical laboratory investigation
(tab. 7), especially medical assessment, must be
taken into consideration.
17. The diagram showing the Steps in clinical läboratöry
investigations also includes biological influence
factors and interference factors (17,18) that can
affect the analytical result. These factors must be
taken into consideration in assessing results.
Biological influence factors lead to changes in vivo
in the clinical chemical parameter. They alwäys
have the patient äs their point of reference. Their
influence is independent ofthe specificity ofthe
analytical method.
18. It is ilöt sufficient to deterinine only a "total error"
(19, 20). instead, one should specify an upper limit
for the random error and an upper limit for the
systematic error. Only then is it possible to estimate
the effect of these errors on medical assessment.
If the limits are given for the total error only, then
two extreme cases are possible.
l. Method without systematic error but with un-
necessarily poor precision.
2.Method with large systematic error that is due to a
lack of specificity öf the method and tiierefore can
be very dependent on the variable matrix ofthe
specimens.
In thefirst case one obtains correct results ön the aver-
äge. Büt in individual cases, due to the effect qf preci-
sion on the width ofthe reference:|nlerval (9, 21), one
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obtains more false positive and false negative findings
than necessary.
In the second case a separate reference sample
group must be evaluated with this method. Otherwise
too many false positive or false negative findings are
obtained at the decision limit.
Therefore, in deciding on the maximum allowable
deviation from the reference method value for a
given constituent, the effects of the random and
systematic components must be estimated.
19. This means that for internal quality control there
should be separate precision control (Shewhart
control charf) and accuracy control, äs is currently
required in the basic program in the Federal Republic
of Germany.
20. Up to now the allowable levels of imprecision in
internal quality control according to the basic pro-
gram have been based on that which is technically
possible (13,14). For some constituents the upper
limits have been larger than would be desirable from
a clinical standpoint.
In external quality control in the form of inter-
laboratory surveys the decision limits have been set
on the basis of the location and distribution of the
analyticäl results from the particularly high-quality
laboratories serving äs reference läböratories (15).
21. In the new concept for quality control of clinical
laboratory investigations, accuracy should be assessed
by a comparison with reference method values. The
maximum allowable deviations should be flxed öfter
consideration oftheir effect on medical assessment
of the analyticäl results.
22. In medical assessment two methods of assessment
(9) are in commpn use.
1. Longitudinal assessment. This is the comparison of
ä result from a given patient with earlier results
ffpm the same patient.
2. Tfänsverse assessment. This is the comparison of a
result with the reference interval for a representa-
tive feference populatiqn.
»
23. In the longitudinal assessment of two analyticäl
results the critical difference (22), which is referred
tö äs "repeatability" in the ISO Draft International
Standard 5725, can be used (täb. 8). Its value is
dependent upon the day-tö-day Standard deviation of
the individual values. The critical difference is based
on the following consideratipns. If two random
variables are independent and have the same expected
value and the same Standard deviation , the Standard
deviation oftheir difference isV2 . Therefore, for
Gaussi&n distributed or approximately Gaussizn
distributed random variables, the probability that the
absolute value of the difference is less than or equal
to 2>/2 is about 95 percent.
The day-to-day Standard deviation from internal
precision cöntrol (n > 30) can be used for .
Tab. 8. Critieal difference.
d = X! -X2
where xj and x2 are analyticäl results from single determinations
p(IDI < 2 · /2- ) -0.95
where D = difference between two random variables
d k = 2 · vT· ST- 2.82· ST
where d^ = critical difference
ST = Standard deviation from day to day
Example: determination of serum Chloride
xi = 100 mmol/1, x2 = 108 mmol/1, ST = 2 mmol/1,
dk = 2.82 · 2 = 5.64, Idl = 1100 - 1081 = 8 > 5.64
If the absolute value of the difference between two
analyticäl results from single determinations is
greater than the critical difference, then from an
analyticäl point of view the results can be regarded
äs being different.
24. Transverse assessment is used in three different situa-
tions.
1. Comparison with a reference interval (23, 24), e.g.
serum potassium;
2. Comparison with a decision limit\
3. Comparison with a theräpeutic ränge.
25. Comparison with a reference interval
The total variance of the reference values (SRV) of
a reference sample group is dependent on a number
of components (tab. 9).
The width of the reference interval depends on the
same components.
Tab. 9. Variation of the reference values (reference population).
Variation Numerical value
Intraindividual -
Interindividual —
Biological —
Total -
Other -
(e.g. specimen eollection)
SB intra
SB inter
SB = V SB intra +
SB = v SB * SAD
so
SB inter
*
s
°
SB = biological Variation
SAD ~ analyticäl between-day imprecision
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The biological Variation is quite different for dif-
ferent constituents. For highly precise homeostatic
regulation such äs S-sodium, S-calcium and S-
chloride1) it can be less than 2%, for intermediate
degrees of regulation such äs S-potassium, S^-glucose,
S-cholesterol and S-phosphate1) it can be 5% to
10%, and for end products of metabolism such äs
urea and uric acid and cell enzymes in serum such äs
aspartate aminotransferase it can be äs high äs 25%.
In each case different requirements must be made
regarding the level ofday-to-day precision needed
because of the effects on medical assessment (25,
9,26).
The most rigid requirements:
SB
SAD
If the biological Variation is unknown:
reference interval .
SAD'
26. Comparison with a decision limit
In a comparison with a decision limit, äs is the case
for the oral glucose tolerance test, quotients should
be calculated äs shown in Statement 25; for an
example of the distribution of values at the decision
limit see figure l (27).
180
o>
160
l
>
° 120
m
100
v
l
100g 75g
Glucose lood
Fig. 1. Blood glucose concentration of 18 patients with sut>
clinical diabetes (disturbed glucose tolerance) 120
minutes after oral administration of 75 g and 100 g
of glucose (x + S.E.M.).
Modified fromBachmann, published in I.e. (20).
l) S = serum
27. The procedure with transverse assessment by meäns
of a comparison with the therapeutic ränge is still to
be discussed and agreed upon.
28. For internal accuracy control the maximum ättow-
able deviation from the reference method välue
should not be greater than plus ör minus twice
(28.1) or, äs an alternative, plus or minus three
times (28.2) the maximum allowable Standard
deviation from day to däy.
29. The decision limitsfor interlaboratory surveys
should be fixed in the same manner äs the maximum
allowable deviations for internal quality control
(29.1) or, äs an alternative, they should be l H
times the allowable deviation M intemal accuracy
control (29.2).
It appears to be absolutely essential, however, to
check every control specimen to be used in an
interlabpratpry survey to see whether the results
from three reference laboratories obtained with the
best available röutine methods are actually within
these liinits. This evaluation should take the form
of a Iong4erm interlaboratory survey, for example
such äs we carry out for ässigned välue detennina-
tion(15).
At the same time this would provide documentation
to the participants in interlabpratory surveys pf the
suitability of a given contröl specimen.
30. Effects on medical action
The intrpduction of accuracy töntrol via a
parison with the reference method välue and th?
üse of decision limits that are derived from cliiiical
requirements would bring the clinical laborätory
ana:lysis a large step closer to the goäl of correct
analytical results. This would induce üsefs to give
preferenee again to the more reliable and especially
more specific methods.
Analytical results and findings obtained with differ-
ent methods in different laboratories could then be
compared with each other with a tevel of relability
adequate for clinical purposes. In addition^ the deter-
mination of method-dependeiit jreference values and
the reference intervals based on >them might become
unnecessary.
The large number öf interference fäctors in -
specific methods that have to be eonsidered in the
medicial assessment would definitely not increäse
and would pröbably actually decrease/
All of these advantages of a quality cpntrpl System
invölving reference method values would justify
° the cost of such a program because of the increase
in the reliäbility of the findings. f
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This paper was prepared at the request of the Com-
mission on Standardization of the German Society for
Clinical Chemistry and presented and discussed in
Munich on April 27,1982 at the Joint Meeting of the
Commissions ori Standardization of the European
Countries on the occasion of Biochemische Analytik.
Comments and suggestions would be welcomed and
should be sent directly to the author.
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